Sentences with phrase «on cognitive disease»

Not exact matches

Fernando Pagan, a GUMC associate professor of neurology who directs the Movement Disorders Program at MedStar Georgetown University Hospital, said that to his knowledge, the study «represents the first time a therapy appears to reverse — to a greater or lesser degree depending on stage of disease — cognitive and motor decline in patients with these neurodegenerative disorders.»

Long - term studies of both problems and potential benefit of Kona coffee drank by elderly people, including assessment on symptoms of Alzheimer's disease and cognitive impairment, are not conclusive.

Long - term studies of both risk and potential benefit of drinking Kona by elderly people, including assessment on symptoms of Alzheimer's disease and cognitive impairment, are not conclusive.

Articles explore: the idea that violence should be thought of as a public health problem analogous to infectious disease; examine from a scientific perspective the impacts on children's social, emotional, and cognitive development of growing up in a violent community; share first - hand insights from children and caregivers; and explore various interventions, from the favelas of Recife, Brazil, to the inner cities of Chicago, Illinois, United States (US), and Glasgow, Scotland, which are offering a tangible sense of hope.

«Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal.

After undergoing the complex process, nine of the 10 participants, who suffered from cognitive impairment or memory loss associated with Alzheimer's, displayed improvement in memory three to six months into the program — a joint venture between the Mary S. Easton Center for Alzheimer's Disease Research at UCLA and the Buck Institute for Research on Aging.

After controlling for factors known to influence brain volume and cognitive test scores, such as age and gender, the researchers found that a higher self - reported frequency of game playing was significantly associated with greater brain volume in several regions involved in Alzheimer's disease (such as the hippocampus) and with higher cognitive test scores on memory and executive function.

For years now the gold standard for R&D in Alzheimer's disease has focused on generating convincing evidence that any new therapy being studied could slow the cognitive decline of patients and help preserve their ability to perform the kind of daily functions that can keep a patient independent for a longer period of time.

A drug used to slow cognitive decline in Alzheimer's disease could offer clues on how drugs might one day be able to reverse brain changes that affect learning and memory in teens and young adults who binge drink.

A study of older adults at risk of late - onset Alzheimer's disease found that those who consumed more omega - 3 fatty acids did better than their peers on tests of cognitive flexibility — the ability to efficiently switch between tasks — and had a bigger anterior cingulate cortex, a brain region known to contribute to cognitive flexibility.

The Centers for Disease Control and Prevention and the National Institute on Drug Abuse stress the potential for long - term cognitive impairment, problems with attention and coordination and other risk - taking behaviors due to heavy marijuana use.

The findings could shed light on diseases like Alzheimer's and help explain the cognitive decline that accompanies the disease.

In a phase 2 trial of 321 people with mild to moderate disease, those on the drug stayed at about the same cognitive level for up to 19 months, while those on the placebo got worse.

In Alzheimer's disease, this loss of synapses occurs very early on, when people still only have mild cognitive impairment, and long before the nerve cells themselves die.

Noting that the prescription of PPIs is on the rise among middle - aged and older adults, a team of researchers designed a new study to examine PPIs and the risk of dementia, mild cognitive impairment, and Alzheimer's disease.

Particularly interesting was the discovery that the thickness of the gray matter in the brain's temporal and prefrontal regions — the structures that are critical for language and for higher - order cognitive functions like self - control and problem - solving — were the most promising candidate traits for genetic mapping, based on both their strong genetic basis and association with the disease.

A $ 1.7 million drug discovery effort to identify molecular and genetic risk factors and new therapeutic targets for cognitive decline and Alzheimer's disease, based on data from the Religious Order Study and the Rush Memory and Aging Project.

«Individuals showing poor balance on one leg should receive increased attention, as this may indicate an increased risk for brain disease and cognitive decline.»

A new Concordia study goes further, however, focusing specifically on the effects of knowing a second language for patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI; a risk state for AD).

White matter hyperintensities, which appear as bright spots on brain MR images, are associated with accelerated motor and cognitive decline, Alzheimer's disease, stroke and death.

Dr. Palop's research focuses on understanding the neural processes underlying cognitive decline in Alzheimer's disease (AD) and in neurological conditions associated with destabilization of neuronal networks, such as epilepsy, autism, or schizophrenia.

She enrolls and manages patients on several trials including: the A4 prevention trial, the BAN20401 study for patients with Mild Cognitive Impairment and very early Alzheimer's Disease, the NOBLE Study and theExpedition 3 study.

She directed The Johns Hopkins Center of Excellence for Aging Research, the Center on Aging and Health, and the Division of Geriatric Medicine and Gerontology, and led major multidisciplinary research programs on the causes and consequences of frailty, cardiovascular disease, cognitive impairment and disability in older adults, and approaches to prevention.

Building on research that identified a rare genetic mutation in Italian people that leads to the early onset of Alzheimer's and one in Icelandic people that delays the onset of the condition, a researcher at the University of British Columbia has discovered that using an enzymatic scissor the right way could stave off the cognitive decline associated with the disease.

Researchers have proposed a radical change in the way Alzheimer's disease is defined, focusing on biological changes in the body, rather than clinical symptoms such as memory loss and cognitive decline.

The research team included Deborah Levine, M.D., MPH, an assistant professor at the University of Michigan Medical School who studies effects of aging, lifestyle and disease on different aspects of thinking ability, also called cognitive function.

A study of patients with early Parkinson's disease found that groups with lower levels of vitamin B12 faced on average a more rapid acceleration of both motor and cognitive symptoms, which slowed in some cases after taking a daily multivitamin.

He currently works as a research assistant on the HOPE study, which tracks the cognitive abilities of elderly adults to stimulate research into understanding both normal cognitive aging and Alzheimer's disease.

The grants will focus on Alzheimer's disease and on age - related cognitive change — changes in thinking, learning, and memory that can come with growing older.

He oversees the Cerebrovascular Disease and Aging Laboratories, which focus on migraine, stroke, epilepsy and cognitive decline from aging.

The NIA provides information on age - related cognitive change and neurodegenerative disease specifically at its Alzheimer's Disease Education and Referral (ADEAR) Center at www.nia.nih.gov/alzhdisease specifically at its Alzheimer's Disease Education and Referral (ADEAR) Center at www.nia.nih.gov/alzhDisease Education and Referral (ADEAR) Center at www.nia.nih.gov/alzheimers.

1/8/2008 UCSD Clinical Trial to Assess Effects of Drug Regimens on HIV - Related Neuro - Cognitive Impairment A clinical trial is being conducted by researchers at UCSD's HIV Neurobehavioral Research Center (HNRC) to discern which antiretroviral treatments are most effective in treating HIV - related disease in the brain and central nervous system.

BIIB054: Racing Under the Radar Biotech pioneer Biogen has been rather quiet about their work on their AS - targeting antibody BIIB054 — unlike their widely - heralded Aducanumab, another amyloSENS - style immunotherapy, which has generated enormous excitement for what seems to be the clearest - cut effect on both beta - amyloid and problems with cognitive function in people with Alzheimer's disease.

In particular his work is focused on how this receptor may affect cognitive processes, and how this relates to Alzheimer's disease.

Qualified investigators can obtain: (1) cleaned, quality control checked sequence data, (2) information on the composition of the study cohorts (e.g. case - control, family based, and epidemiology cohorts), (3) descriptions of the study cohorts included in the analysis, and (4) accompanying phenotypic information such as age at disease onset, gender, diagnostic status, and cognitive measures.

Moreover, PHENONIM - ICS is involved in European projects presenting a strong impact on human health: Interreg CARDIOGENE (Genetic mechanisms of cardiovascular diseases), GENCODYS (Genetic and epigenetic networks involved in cognitive dysfunctions), AgedBrainSYSBIO (Basic studies of brain aging), as well as projects in partnership with industry: MAGenTA (an Industrial Strategic Innovation project supported by Bpifrance about the treatment of major urogenital diseases) and CanPathPro (H2020 program), to develop a predictive modeling platform of signaling pathways involved in cancers.

Freitas et al (2011) performed a systematic search of all studies using non-invasive stimulation in Alzheimer's disease (AD) and reviewed all 29 identified articles; 24 focused on measures of motor cortical reactivity and (local) plasticity and functional connectivity, with 8 of these studies assessing also effects of pharmacological agents, and 5 studies focused on the enhancement of cognitive function in AD.

Of special note today: A randomized double blind controlled clinical trial on the impacts of probiotics on Alzheimer's demonstrated an improvement in cognitive function, triglycerides, insulin sensitivity and C reactive protein; and a meta - analysis of the lung microbiome in tuberculosis identified specific species that are characteristic of the disease.

Speech problems may reflect not just less fluency and communication prowess, but also early signs of cognitive decline that could pave the way for Alzheimer's disease later on.

Further research published in the journal Neuropsychology studied the effects of being bilingual on the executive functioning of two groups of participants: 75 people with a diagnosis of Alzheimer's disease and 74 with a diagnosis of mild cognitive impairment, a condition that sometimes progresses into Alzheimer's disease.

The operationalization of mild cognitive impairment (MCI) led to targeting earlier symptomatic cases of the illness and treatment strategies based less on pathology and more on a chance to halt or slow decline than there would be earlier in the disease.1 With the development of amyloid imaging, MCI due to AD diagnosis was refined, 2 and early - stage AD was extended further to include preclinical AD, 3 wherein a positive amyloid positron emission tomography (PET) scan or diagnostic low levels of cerebrospinal fluid β - amyloid (Aβ) indicated the presence of pathology in people who were cognitively normal.

The Hereditary Disease Foundation facilitates collaborative and innovative scientific research to further the understanding of Huntington's disease, a genetic disorder that strikes in early - to mid-adulthood, destroying brain cells, and bringing on severe and progressive declines in personality, cognitive ability, and moDisease Foundation facilitates collaborative and innovative scientific research to further the understanding of Huntington's disease, a genetic disorder that strikes in early - to mid-adulthood, destroying brain cells, and bringing on severe and progressive declines in personality, cognitive ability, and modisease, a genetic disorder that strikes in early - to mid-adulthood, destroying brain cells, and bringing on severe and progressive declines in personality, cognitive ability, and mobility.

Examine prospectively the effects of coffee / caffeine on cognitive decline, neurodegenerative diseases, and depression.

«Jorge has developed a highly innovative research program focusing on the role of interneuron and network dysfunction in Alzheimer's disease and other cognitive disorders,» said Lennart Mucke, MD, director of the Gladstone Institute of Neurological Ddisease and other cognitive disorders,» said Lennart Mucke, MD, director of the Gladstone Institute of Neurological DiseaseDisease.

Other research has suggested that supplementing might slow deterioration in cognition for people with Alzheimer's disease, but more research is needed on the effects of this antioxidant on cognitive function and brain health.

On that list is Vitamin E, a powerful antioxidant found in oils, nuts, seeds, whole grains and leafy green vegetables, which is associated with slower cognitive decline, a lower risk of dementia, and reduced accumulation of beta - amyloid proteins — a key culprit in Alzheimer's disease.

At the start of the study, the researchers performed MRI scans on 35 people with mild cognitive impairment, which is a risk factor for Alzheimer's disease.

With degenerative and cognitive - based diseases on the rise from autism and ADHD in children to Parkison's and Alzheimer's in adults, uncovering the nuances in the relationship between the brain and the gut has never been more important.

«Some of the benefits of coffee seem to be linked to the caffeine content, like the positive effects on cognitive function and the decreased risk for neurodegenerative diseases like Parkinson's,» he says.

But given the fact that soy has been linked to cognitive decline, dementia, brain atrophy and neurodegenerative disease, it would not be wise to start swigging soy milk or feasting on tofu.